To evaluate the therapeutic potential of targeting the PTN–PTPRZ1 paracrine signalling in GBM treatment, we examined whether a specific anti-PTPRZ1 antibody could inhibit GSC-derived tumour growth. This evidence concerns the gene PTN and glioblastoma.